How to maintain drugs in the advanced stage of lung cancer

Lung cancer is the most common cancer in the world, with an annual increase of 6.5438+0.5 million cases, of which 85% are non-small cell lung cancer. Non-small cell lung cancer progresses very rapidly, and the 5-year survival rate of patients with advanced non-small cell lung cancer is less than 5%. The main function of treatment is to prolong the survival time of patients without disease progression and reduce side effects, mainly by adopting some standard treatment schemes to control the disease. When the standard treatment scheme is over, we can only wait for the disease to recur or metastasize before continuing the second-line treatment. However, the research results at the annual meeting of the American Society of Clinical Oncology this year show us the role of patients with advanced non-small cell lung cancer in maintaining treatment after the standard first-line treatment. At the annual meeting of the American Society of Clinical Oncology in 2009, Roche announced the results of the third ATLAS study. The results show that in the treatment of advanced non-small cell lung cancer (NSCLC), compared with Avastin alone, the combination of Avastin (bevacizumab) and troxertine (erlotinib) as first-line maintenance therapy can prolong the disease-free survival by 39% (progression-free survival or PFS, the main end point of the study). A large number of studies have proved that Avastin-based treatment can bring patients with advanced non-small cell lung cancer more than 12 months of survival time-the longest known survival time. ATLAS research results show that after the initial Avastin treatment and chemotherapy, the disease-free survival time can be extended to 4.8 months by the combination of Avastin and Trake, while only Avastin maintenance treatment can be extended to 3.7 months. Advanced non-small cell lung cancer is progressing rapidly, which represents another milestone breakthrough in the treatment of this disease. It is important to achieve the improvement effect without continuing chemotherapy. Another phase III study, SATURN, confirmed the value of Trocquer in the maintenance treatment of advanced non-small cell lung cancer, and this result was also reported at this year's annual meeting of the American Society of Clinical Oncology. In the SATURN trial, patients with tumor progression after initial chemotherapy received maintenance treatment. The data showed that compared with the placebo group, the survival time of patients without disease progression in Trocquer treatment group was significantly prolonged by 465,438 0%, which was statistically significant, and both squamous cell lung cancer patients and non-squamous cell lung cancer patients were improved. Professor Federico Cappuzzo of IRCCS clinic in Milan is the main researcher of Saturn research. In these two studies, he said: "prolonging the survival time of patients without disease progression is a key goal of lung cancer treatment." ATLAS and Saturn undoubtedly bring good news to patients and doctors. Prolonging the time of inhibiting tumor growth as much as possible can not only relieve symptoms, but also improve the quality of life of patients. More importantly, this goal can be achieved without chemotherapy, because the side effects of chemotherapy have greatly increased the physical and psychological burden borne by many cancer patients. " At present, Trocquer has been listed in China, and Avastin (bevacizumab) is currently undergoing clinical trials in China and will be listed in the future. ATLAS research ATLAS is a global, multicenter, randomized, double-blind, placebo-controlled study. * * We selected 1, 160 patients with locally advanced, recurrent or metastatic non-small cell lung cancer. First, patients received four cycles of first-line treatment, that is, Avastin and researchers chose different platinum chemotherapy regimens. Patients with no tumor progression were randomly assigned to receive maintenance treatment of Avastin combined with Trask or Avastin combined with placebo until the disease progressed. ATLAS study reached the main end point, and the survival time of patients without disease progression was significantly prolonged, which was statistically significant; Compared with patients who received Avastin monotherapy, it increased by 39%. The median progression-free survival (PFS) of the combined treatment group was 4.8 months, while that of the Avastin monotherapy group was only 3.7 months, which was statistically significant. SATURN study is a global, multi-center, double-blind, randomized, prospective phase III study. The research object is patients with advanced, recurrent or metastatic non-small cell lung cancer who have not progressed after receiving first-line platinum chemotherapy, aiming at evaluating the efficacy of Traxel or placebo. The study * * * involved 880 patients from about 160 centers; 438 patients received Trocquer treatment, and 45/kloc-0 patients received placebo treatment. The study reached the main end point, and the survival time of patients without disease progression was significantly prolonged, which was statistically significant; It increased by 4 1% compared with the placebo group. Adverse events: The results of ATLS and Saturn studies are consistent with previous studies on Avastin or Trafigura, respectively, and the experiments of evaluating these two drugs at the same time. No new security information appears. AvastinAvastin is an antibody that can specifically bind and block VEGF (vascular endothelial growth factor). VEGF is a key factor to promote tumor angiogenesis, which is an essential process for tumor growth and spread (metastasis) to other parts of the body. Avastin has a definite mechanism of action, which can control the growth and metastasis of tumor, but has limited effect on the side effects of chemotherapy. Trocquer Trocquer is different from traditional chemotherapy drugs, which can effectively inhibit EGFR. As a second-line treatment drug, Trocquer is the first and only oral preparation for EGFR, which has been proved to significantly improve the symptoms of patients with advanced lung cancer, prolong the survival time and have no side effects of chemotherapy.